Association between NAT2, CYP1A1, and CYP1A2 genotypes, heterocyclic aromatic amines, and prostate cancer risk: a case control study in Japan

Table 3 Association between HAA intake and prostate cancer

	Mean (SD)	Cases	Controls	OR (95% CI)^a
Total HAAs (ng/day)
Low tertile	17.5 (7.1)	100	131	1.00
Moderate tertile	35.6 (5.3)	108	124	1.14 (0.83–1.58)
High tertile	72.9 (29.2)	143	96	1.90 (1.40–2.59)
Trend P^b				< 0.001
Total Trp-P-1 (ng/day)
Low tertile	0.44 (0.55)	104	129	1.00
Moderate tertile	2.9 (0.55)	104	128	1.05 (0.76–1.45)
High tertile	7.2 (5.0)	143	94	1.92 (1.42–2.61)
Trend P				< 0.001
Total MeIQ (ng/day)
Low tertile	2.3 (0.93)	100	131	1.00
Moderate tertile	4.5 (0.57)	109	123	1.18 (0.85–1.63)
High tertile	9.0 (3.7)	142	97	1.87 (1.38–2.55)
Trend P				< 0.001
Total MeIQx (ng/day)
Low tertile	2.4 (0.98)	99	132	1.00
Moderate tertile	4.9 (0.71)	102	130	1.05 (0.76–1.46)
High tertile	9.9 (3.9)	150	89	2.25 (1.65–3.06)
Trend P				< 0.001
Total PhIP (ng/day)
Low tertile	10.5 (4.2)	102	129	1.00
Moderate tertile	21.5 (3.2)	106	126	1.06 (0.77–1.48)
High tertile	44.7 (18.3)	143	96	1.84 (1.35–2.50)
Trend P				< 0.001

BMI body mass index; OR oratio; 95% CI 95% confidence interval; HAA heterocyclic aromatic amine; Trp-P-1 3-Amino-1, 4-dimethyl-5H-pyrido[4, 3-b]indole; MeIQ 2-Amino-3,4-dimethylimidazo[4,5-f]quinoline; MeIQx 2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline; PhIP 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
^aORs (95% CI) adjusted by conditional logistic regression for alcohol intake, smoking status, BMI, family history of prostate cancer, and total energy intake
^b P value for Cochran–Armitage test for trend

ISSN: 1347-4715